<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23168" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hypercoagulability</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Senst</surname>
            <given-names>Benjamin</given-names>
          </name>
          <aff>Universit&#x000e4;tsklinikum Halle</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tadi</surname>
            <given-names>Prasanna</given-names>
          </name>
          <aff>Asram Medical College, Eluru, India</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Basit</surname>
            <given-names>Hajira</given-names>
          </name>
          <aff>Brookdale University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jan</surname>
            <given-names>Arif</given-names>
          </name>
          <aff>Drexel University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Benjamin Senst declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prasanna Tadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hajira Basit declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arif Jan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23168.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hypercoagulability or thrombophilia is the increased tendency of blood to thrombose. A normal and healthy response to bleeding for maintaining hemostasis involves the formation of a stable clot, and the process is called coagulation. Hypercoagulability describes the pathologic state of exaggerated coagulation or coagulation in the absence of bleeding. Arterial thrombosis, such as in myocardial infarction and stroke, is different from venous thromboses, such as deep venous thrombosis (DVT) and pulmonary embolism (PE). This activity reviews the cause and presentation of hypercoagulability and highlights the role of the interprofessional team in its management</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the causes of hypercoagulability.</p></list-item><list-item><p>Describe the evaluation of a patient with hypercoagulability.</p></list-item><list-item><p>Summarize the treatment of hypercoagulability.</p></list-item><list-item><p>Explain modalities to improve care coordination among interprofessional team members in order to improve outcomes for patients affected by hypercoagulability.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23168&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23168">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23168.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hypercoagulability or thrombophilia is the increased tendency of blood to thrombose. A normal and healthy response to bleeding for maintaining hemostasis involves the formation of a stable clot, and the process is called coagulation.&#x000a0; Hypercoagulability describes the pathologic state of exaggerated coagulation or coagulation in the absence of bleeding. Different constituents of the blood interact to create a thrombus. Arterial thrombosis, such as in myocardial infarction and stroke, is different from venous thromboses, such as deep venous thrombosis (DVT) and pulmonary embolism (PE). Pathophysiology and treatment differ for arterial and venous thrombosis, but risk factors overlap.<xref ref-type="bibr" rid="article-23168.r1">[1]</xref><xref ref-type="bibr" rid="article-23168.r2">[2]</xref> Thromboembolism&#x000a0;describes the migration of a local thrombus to distant areas leading to&#x000a0;luminal obstruction.&#x000a0;Different hypercoagulable states and thrombophilic diseases cause hypercoagulability. As early as 1906 Wasserman et al., described the antiphospholipid syndrome. In 1965 Egeberg et al., discovered&#x000a0;antithrombin III deficiency.<xref ref-type="bibr" rid="article-23168.r3">[3]</xref> During the 1980s protein C (Griffin, 1981) and protein S (Comp, 1984) deficiencies were introduced. Dahlb&#x000e4;ck discovered activated protein C resistance in 1993, which is commonly caused by the factor V Leiden mutation.<xref ref-type="bibr" rid="article-23168.r4">[4]</xref><xref ref-type="bibr" rid="article-23168.r5">[5]</xref><xref ref-type="bibr" rid="article-23168.r6">[6]</xref></p>
      </sec>
      <sec id="article-23168.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Hypercoagulability disorders&#x000a0;are either acquired or inherited.<xref ref-type="bibr" rid="article-23168.r7">[7]</xref> However, actual thrombosis occurs due to the interplay of both genetic and environmental factors and follows the multiple hit hypothesis,<xref ref-type="bibr" rid="article-23168.r8">[8]</xref><xref ref-type="bibr" rid="article-23168.r9">[9]</xref><xref ref-type="bibr" rid="article-23168.r10">[10]</xref>&#x000a0;thus explaining the inter-individual differences observed in patients with&#x000a0;inherited mutations.<xref ref-type="bibr" rid="article-23168.r11">[11]</xref>&#x000a0;Genetic factors can now be identified in up to 30% of patients with VTE and are mainly attributable to factor V Leiden and prothrombin G2021A mutation. These two thrombophilias implicate a weak&#x000a0;thrombotic risk. Other inherited thrombophilias are rare such as antithrombin III, protein C and protein S deficiency (around 1% in the general population) but pose a higher risk for thrombosis. Acquired factors also&#x000a0;influence the coagulation cascade and include surgery, pregnancy, hormonal replacement therapy, contraception, malignancy, inflammation, infection, and heparin-induced thrombocytopenia.<xref ref-type="bibr" rid="article-23168.r12">[12]</xref><xref ref-type="bibr" rid="article-23168.r11">[11]</xref></p>
      </sec>
      <sec id="article-23168.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Venous thromboembolism is the second most common cardiovascular disorder following myocardial infarction; it is more frequent than stroke. Its incidence&#x000a0;ranges between 1 and 5 in 1000 per year in the general population.<xref ref-type="bibr" rid="article-23168.r13">[13]</xref>&#x000a0;The incidence is age dependent with 1 per 100000 per year in children and increases to 1 per 1000 per year in adults and 1/100/year in the elderly.<xref ref-type="bibr" rid="article-23168.r14">[14]</xref> Thomas reported the frequency of thrombophilias with APS, APC resistance, elevated factor VIII as 25 to 28%; protein C deficiency, protein S deficiency, hyperhomocysteinemia and prothrombin mutation as 5 to 10%.<xref ref-type="bibr" rid="article-23168.r8">[8]</xref>&#x000a0;Up to 4% of strokes are due to hypercoagulability disorders.</p>
      </sec>
      <sec id="article-23168.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Coagulation is an inherent property of the hematologic system and under healthy conditions, normal blood flow is maintained by the balance between the pro-coagulant and anti-thrombotic factors. A hypercoagulable state and subsequent thromboembolism is a result of overactivity of pro-coagulant factors or a deficiency in anti-coagulants. The interplay of factors is complicated - coagulation activators and inhibitors and their production and degradation (quantitative) and functional properties (qualitative) all influence thrombosis. The triad of <italic toggle="yes">hypercoagulability, vascular stasis and vascular trauma</italic> as described by Virchow in 1856 still holds and remains the harbinger of&#x000a0;vascular thrombosis.<xref ref-type="bibr" rid="article-23168.r15">[15]</xref><xref ref-type="bibr" rid="article-23168.r16">[16]</xref><xref ref-type="bibr" rid="article-23168.r17">[17]</xref>&#x000a0;Arterial thrombosis results from atherosclerotic plaque rupture around which a platelet-rich white thrombus forms. Stasis behind venous valves contributes to venous thrombosis and red thrombus. Mutations influence coagulation depending on whether they are present in heterozygous or homozygous genotype.<xref ref-type="bibr" rid="article-23168.r18">[18]</xref></p>
        <p>Some Coagulation Disorders include the following:&#x000a0;</p>
        <p><bold>Antithrombin III (ATIII)</bold>&#x000a0;deficiency. Antithrombin III binds to heparin on endothelial cells and forms a complex with thrombin (thrombin-antithrombin (TAT) complex) thus inhibiting coagulation. The prevalence&#x000a0;may be 1 in 500 in the general population. Its deficiency may present as early age thrombosis (less than 50 years old) and carries the highest risk for thrombotic events among the inherited thrombophilias. Antithrombin is synthesized in the liver but is not vitamin K-dependent. ATIII deficiency can occur as a consequence of reduced synthesis (liver damage) or increased loss (nephrotic syndrome, enteropathy, DIC, sepsis, burn, trauma, microangiopathy, and cardiopulmonary bypass surgery).<xref ref-type="bibr" rid="article-23168.r19">[19]</xref> Qualitative defects of ATIII (type II deficiency) describe mutations which either affect the heparin-binding site (HBS), the reactive site (RS) or result in pleiotropic effects (PE).&#x000a0;Homozygous ATIII deficiency is incompatible with life unless affecting the heparin-binding site.<xref ref-type="bibr" rid="article-23168.r11">[11]</xref><xref ref-type="bibr" rid="article-23168.r20">[20]</xref>&#x000a0;Usually these patients present with venous thrombosis and less likely with arterial thrombosis.&#x000a0;</p>
        <p><bold>Protein C deficiency</bold> can present as thrombosis in teenagers. Protein C and S deficiency&#x000a0;may be&#x000a0;inherited but is also inducable by&#x000a0;liver dysfunction, vitamin k antagonists, renal failure, DIC, and active thrombosis.&#x000a0;Protein S enhances the effect of activated protein C. Protein S deficiency can be classified as type I (reduced quantity of protein S), type II (low APC activity), and type III (low free protein S due to increased binding to the complement factor C4b). The interaction of protein S with C4, which is an active phase reactant exemplifies the relation of coagulation, inflammation, and autoimmunity.&#x000a0;<xref ref-type="bibr" rid="article-23168.r19">[19]</xref>&#x000a0;The half-life of protein C is shorter than the half-life of other vitamin K-dependent coagulation factors, hence the risk of increased coagulation with the initiation of vitamin K antagonists and need for bridging with parenteral heparin (warfarin-induced skin necrosis).<xref ref-type="bibr" rid="article-23168.r11">[11]</xref><xref ref-type="bibr" rid="article-23168.r20">[20]</xref></p>
        <p>Protein C interacts with thrombomodulin to become <bold>activated protein C (APC)</bold>. APC has anticoagulant, anti-inflammatory, and cytoprotective properties and has been proposed for the treatment of sepsis. The signal cascade leading to APC can become distorted through many acquired or inherited mechanisms leading to APC resistance. Activated protein C inactivates coagulation factors V and VIII. The factor V Leiden mutation is a common cause for APC resistance&#x000a0;and&#x000a0;the most&#x000a0;frequent genetic&#x000a0;thrombophilia.<xref ref-type="bibr" rid="article-23168.r19">[19]</xref>&#x000a0;The FV Leiden mutation is also suspected of increasing the risk of arterial thrombosis.<xref ref-type="bibr" rid="article-23168.r11">[11]</xref>&#x000a0;Other FV mutations&#x000a0;include&#x000a0;factor V Cambridge and factor V Hong Kong.<xref ref-type="bibr" rid="article-23168.r12">[12]</xref><xref ref-type="bibr" rid="article-23168.r20">[20]</xref>&#x000a0;The most common genetic risk factor for thrombophilia is Factor V Leiden mutation. It increases the risk of thrombosis by enhanced thrombin production.&#x000a0;</p>
        <p>Prothrombin is the precursor of thrombin, which is factor II. The <bold>prothrombin G20210A mutation</bold> is the second most common inherited risk factor for thrombosis and leads to increased levels of prothrombin which&#x000a0;demonstrates&#x000a0;a higher risk for arterial and venous thrombotic events.<xref ref-type="bibr" rid="article-23168.r12">[12]</xref><xref ref-type="bibr" rid="article-23168.r11">[11]</xref><xref ref-type="bibr" rid="article-23168.r20">[20]</xref>&#x000a0;It is due to a single point mutation. It is seen commonly in Caucasians.&#x000a0;</p>
        <p><bold>Hyperhomocysteinemia</bold> is associated with premature atherosclerosis and thrombosis and caused by defects of the&#x000a0;methionine metabolic pathway. Deficiencies of cofactors of this pathway such as vitamin B6, B12, and folate or defects of enzymes such as cystathionine beta-synthase (CBS) or methylenetetrahydrofolate reductase (MTHFR) decrease the efficiency of homocysteine metabolism. Furthermore renal failure, hypothyroidism, and drugs such as methotrexate, phenytoin, and carbamazepine increase homocysteine levels. On the other hand, lowering homocysteine levels has not been shown to reduce thrombotic risk.<xref ref-type="bibr" rid="article-23168.r19">[19]</xref><xref ref-type="bibr" rid="article-23168.r12">[12]</xref><xref ref-type="bibr" rid="article-23168.r8">[8]</xref><xref ref-type="bibr" rid="article-23168.r11">[11]</xref><xref ref-type="bibr" rid="article-23168.r20">[20]</xref><xref ref-type="bibr" rid="article-23168.r21">[21]</xref></p>
        <p><bold>Elevated factor VIII (FVIII)</bold> increases the risk of thrombosis. African-Americans appear to have higher levels whereas individuals with blood group O tend to have lower levels of FVIII. High levels of&#x000a0;this factor also correlate with acute phase reactions, estrogen usage, pregnancy, and after aerobic exercise.<xref ref-type="bibr" rid="article-23168.r19">[19]</xref>&#x000a0;A high FVIII level may cause APC resistance not due to FV mutation.<xref ref-type="bibr" rid="article-23168.r11">[11]</xref> In contrast, low levels of FVIII correlate with bleeding in hemophilia A patients.</p>
        <p><bold>Dysfibrinolysis</bold> includes plasminogen deficiency, dysfibrinogenemia, tissue plasminogen activator (tPA) deficiency, plasminogen activator inhibitor (PAI) increase, and factor XII deficiency, which is involved in plasmin generation. Deficient plasminogen clinically appears similar to protein c deficiency with thrombosis during the teenage years. PAI increase and deficient tPA has an association with diabetes mellitus,<xref ref-type="bibr" rid="article-23168.r22">[22]</xref> inflammatory bowel syndrome and coronary atherosclerosis.<xref ref-type="bibr" rid="article-23168.r8">[8]</xref>&#x000a0;In patients with structural or functional changes to fibrinogen (dysfibrinogenemia) thrombosis or bleeding can occur.<xref ref-type="bibr" rid="article-23168.r11">[11]</xref></p>
        <p>The <bold>sticky platelet syndrome</bold> is an autosomal dominant disease in which platelets coming into contact with epinephrine or adenosine diphosphate (ADP) react to induce hypercoagulability.<xref ref-type="bibr" rid="article-23168.r8">[8]</xref></p>
        <p>The most common acquired thrombophilia is the <bold>antiphospholipid syndrome (APS)</bold> in which antibodies are directed against natural constituents of cell membranes, the phospholipids. These antiphospholipid antibodies (APLA)&#x000a0;occur in 3 to 5% of the&#x000a0;population and&#x000a0;may cause arterial or venous thrombosis and fetal loss. APLAs being tested for include lupus anticoagulant, anticardiolipin, anti-beta-2-glycoprotein. Lupus anticoagulant leads to prolongation of coagulation (aPTT) in vitro but thrombosis in vivo.<xref ref-type="bibr" rid="article-23168.r19">[19]</xref>&#x000a0;Antiphospholipid antibodies may also occur secondary to other diseases (collagen vascular disease or infections) or drugs (phenytoin and cocaine among others).<xref ref-type="bibr" rid="article-23168.r8">[8]</xref>&#x000a0;The most common thrombotic event is deep vein thrombosis. Any patient with stroke and rheumatological disorder should be screened for antiphospholipid antibody syndrome.&#x000a0;</p>
        <p><bold>Malignancy</bold> is the second most common acquired hypercoagulability and leads to a&#x000a0;prothrombotic state through the production of procoagulant factors (tissue factor and cancer procoagulant) and the interaction of tumor cells with blood and vascular endothelium. Stasis from tumor compression, paraproteinemia, and cytokine release&#x000a0;pose an additional risk.<xref ref-type="bibr" rid="article-23168.r23">[23]</xref>&#x000a0;In 85% of cancer patients, cancer procoagulant (CP) is elevated. This enzyme actives factor X thus causing hypercoagulability in cancer patients.<xref ref-type="bibr" rid="article-23168.r23">[23]</xref>&#x000a0;Polycythemia vera poses a thrombotic risk in addition to hyperviscosity.<xref ref-type="bibr" rid="article-23168.r20">[20]</xref>&#x000a0;Migratory thrombophlebitis as a consequence of visceral malignancy is known as Trousseau syndrome. The interaction of malignancy and coagulation is of interest as not only malignancy favors thrombosis but the hemostatic system influences angiogenesis which support tumor growth and spread. Targeting the hemostatic system might offer treatment options for anticancer therapy.<xref ref-type="bibr" rid="article-23168.r24">[24]</xref><xref ref-type="bibr" rid="article-23168.r25">[25]</xref><xref ref-type="bibr" rid="article-23168.r26">[26]</xref></p>
        <p>The extrinsic coagulation pathway trigger is tissue factor (TF) which activates coagulation factor VII. Tissue factor is not expressed under physiologic conditions by endothelial cells but continuously produced by subendothelial (activation of coagulation in case of vessel damage) and malignant cells (association of malignancy and thrombotic events). TF is naturally counteracted by the tissue factor pathway inhibitor (TFPI).<xref ref-type="bibr" rid="article-23168.r27">[27]</xref></p>
        <p>Arterial bypass grafts fail prematurely in smokers. <bold>Smoking</bold> tobacco contains various toxins. Nicotine results in endothelial cell damage. The release of tissue plasminogen activator (tPA) and tissue factor pathway inhibitor (TFPI) get reduced. Carbon monoxide increases the permeability of endothelium to lipids thus leading to atheroma formation.<xref ref-type="bibr" rid="article-23168.r20">[20]</xref></p>
        <p>In general, <bold>exercise</bold> improves the cardiovascular risk profile, but observations of sudden cardiac death in some individuals led investigators to search for causes. Exercise influences coagulation, fibrinolysis, and platelet aggregation.<xref ref-type="bibr" rid="article-23168.r28">[28]</xref> Usually, this is kept in balance but in some individuals, the immediate postexercise period is characterized by a hypercoagulable state with an increase of factor eight (intrinsic pathway activation) and platelet activation.<xref ref-type="bibr" rid="article-23168.r29">[29]</xref><xref ref-type="bibr" rid="article-23168.r30">[30]</xref>&#x000a0;Older individuals&#x000a0;carry more cardiovascular risk factors and are less well trained. Thus they are prone to suffer adverse effects from the temporary hypercoagulable state following exercise.<xref ref-type="bibr" rid="article-23168.r31">[31]</xref>&#x000a0;In the Tromso study regular, moderate-intensity exercise did not significantly impact the risk for thrombosis.<xref ref-type="bibr" rid="article-23168.r32">[32]</xref><xref ref-type="bibr" rid="article-23168.r33">[33]</xref></p>
        <p>The onset of arterial thrombosis (myocardial infarction and stroke) follows a <bold>circadian</bold> pattern being most frequent during the early morning hours.<xref ref-type="bibr" rid="article-23168.r34">[34]</xref> This pattern might be explained by variation in blood pressure and platelet activation.<xref ref-type="bibr" rid="article-23168.r35">[35]</xref><xref ref-type="bibr" rid="article-23168.r36">[36]</xref>&#x000a0;Circadian changes&#x000a0;in blood rheology and coagulation factors during the day have also been reported and might undergo influence by the dietary pattern.<xref ref-type="bibr" rid="article-23168.r37">[37]</xref><xref ref-type="bibr" rid="article-23168.r38">[38]</xref><xref ref-type="bibr" rid="article-23168.r39">[39]</xref></p>
        <p><bold>Endogenous and exogenous hormones</bold> influence coagulation. Oral contraception and hormone replacement therapy&#x000a0;are a risk factor for thrombosis and cardiovascular events.<xref ref-type="bibr" rid="article-23168.r20">[20]</xref> Testosterone therapy can&#x000a0;influence thrombotic risk through&#x000a0;increasing blood pressure, hemoglobin, LDL cholesterol, hyperviscosity, and platelet aggregation.<xref ref-type="bibr" rid="article-23168.r40">[40]</xref><xref ref-type="bibr" rid="article-23168.r41">[41]</xref></p>
        <p>Through the increase of procoagulants (diverse coagulation factors and the number of platelets) and the decrease of anticoagulants (PAI) in addition to stasis caused by compression of the gravid uterus, <bold>pregnancy</bold> presents a time of hypercoagulability extending 2 months into the postpartum period.<xref ref-type="bibr" rid="article-23168.r20">[20]</xref>&#x000a0;This was under evaluation in the MEGA study and LMWH is being tested to prevent miscarriage in pregnant women with inherited thrombophilias in the ALIFE&#x000a0;study.<xref ref-type="bibr" rid="article-23168.r42">[42]</xref><xref ref-type="bibr" rid="article-23168.r43">[43]</xref> The association of pregnancy complications and thrombophilia is subject to ongoing research.<xref ref-type="bibr" rid="article-23168.r44">[44]</xref></p>
        <p>Heparin is a commonly used anticoagulant. Under certain circumstances, arterial and venous thrombosis concomitantly with thrombocytopenia paradoxically results from prolonged heparin administration, which is called<bold> heparin-induced thrombocytopenia (HIT)</bold>. In type-I HIT platelets&#x000a0;show a weak reduction of platelets&#x000a0;and have little clinical consequences. This is in contrast to the strong reduction of thrombocytes and serious sequelae of HIT type-II. The conformational change of heparin following heparin binding to platelet factor 4 triggers antibody production to heparin. Subsequently, monocytes become activated and attack the vascular endothelium leading to thrombotic events.<xref ref-type="bibr" rid="article-23168.r20">[20]</xref></p>
        <p>There is an interplay between <bold>inflammation</bold> and the coagulation system.&#x000a0;Inflammation&#x000a0;triggers a hypercoagulable state.<xref ref-type="bibr" rid="article-23168.r45">[45]</xref>&#x000a0;Endotoxin activates the complement system leading to thrombocytopenia and hypercoagulability.<xref ref-type="bibr" rid="article-23168.r46">[46]</xref> The relation between inflammation and coagulation can be observed clinically in patients with purpura, vasculitis, and septic thromboembolism.<xref ref-type="bibr" rid="article-23168.r47">[47]</xref><xref ref-type="bibr" rid="article-23168.r48">[48]</xref> Coagulation helps to limit the expansion of infection, and some bacteria use fibrinolytic properties to oppose this response. Autoimmune diseases like systemic lupus erythematosus, immune thrombocytopenic purpura, polyarteritis nodosa, polymyositis, dermatomyositis, inflammatory bowel disease, and Behcet's syndrome&#x000a0;increase the risk of thrombotic events.<xref ref-type="bibr" rid="article-23168.r49">[49]</xref><xref ref-type="bibr" rid="article-23168.r50">[50]</xref><xref ref-type="bibr" rid="article-23168.r51">[51]</xref>&#x000a0;The cytomegaly virus (CMV) has correlations to atherogenesis through a change of the cellular lipid metabolism and leukocyte adherence.<xref ref-type="bibr" rid="article-23168.r52">[52]</xref>&#x000a0;</p>
        <p><bold>Trauma</bold> is another acquired hypercoagulable state. Procoagulant disbalance&#x000a0;is more pronounced&#x000a0;during the first 24 hours following injury and&#x000a0;in women. The onset of respiratory distress syndrome and multiorgan failure following trauma has been associated with elevated tissue factor.<xref ref-type="bibr" rid="article-23168.r53">[53]</xref></p>
        <p>Other conditions associated with a hypercoagulable state include myeloproliferative disorders, multiple myeloma,<xref ref-type="bibr" rid="article-23168.r54">[54]</xref> paroxysmal nocturnal&#x000a0;hemoglobinuria, heart failure.<xref ref-type="bibr" rid="article-23168.r55">[55]</xref> The endothelium of the left atrial appendage showed higher expression of tissue factor and plasminogen activator inhibitor compared to the right atrial appendage. This inherent prothrombotic property of the LAA in addition to flow disturbances of atrial fibrillation leads to thromboembolic events.<xref ref-type="bibr" rid="article-23168.r56">[56]</xref></p>
      </sec>
      <sec id="article-23168.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A detailed history is critical to differentiate between provoked and unprovoked thromboembolism and should include demographics, family history, assessment of risk factors, description of symptoms and followed by a standard physical examination. In up to 70% of patients suffering from VTE, a provoking factor is present. One in three patients reports a positive family history.&#x000a0;<xref ref-type="bibr" rid="article-23168.r11">[11]</xref>&#x000a0;Early age thrombosis is defined as thrombotic events occurring in people younger than 40 or 50 years old.&#x000a0;Unusual site thrombosis includes cerebral, jugular (i.e., Lemierre syndrome), splanchnic&#x000a0;<xref ref-type="bibr" rid="article-23168.r57">[57]</xref> and portal (i.e., Budd-Chiari&#x000a0;<xref ref-type="bibr" rid="article-23168.r58">[58]</xref>) and upper extremity veins.&#x000a0;<xref ref-type="bibr" rid="article-23168.r59">[59]</xref>&#x000a0;<xref ref-type="bibr" rid="article-23168.r60">[60]</xref>&#x000a0;<xref ref-type="bibr" rid="article-23168.r61">[61]</xref>&#x000a0;Based on history and physical exam, the Wells score&#x000a0;guides diagnostic workup in first time venous thromboembolism (VTE).</p>
      </sec>
      <sec id="article-23168.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>To diagnose hypercoagulability syndromes, the combination of screening tests, confirmation tests, and risk factors all must merit consideration.<xref ref-type="bibr" rid="article-23168.r19">[19]</xref>&#x000a0;The thrombophilia screen includes functional assays for antithrombin III, protein c and s deficiency, PCR for factor V Leiden mutation and prothrombin G2021A mutation,&#x000a0;testing for antiphospholipid antibodies and homocysteine level.<xref ref-type="bibr" rid="article-23168.r12">[12]</xref>&#x000a0;Additional laboratory investigations include routine coagulation panel, d-dimer,<xref ref-type="bibr" rid="article-23168.r62">[62]</xref> and CBC.</p>
        <p>Moll et al. suggest the "4P" approach, which is patient selection, pretest counseling, proper laboratory test interpretation, and provision of education and advice. Additionally, they created a risk of recurrence triangle to decide based on risk assessment, how long it would take to achieve anticoagulation. Not every patient requires testing for thrombophilia. Testing is not advisable during the acute thrombotic event (rather schedule for 3-month follow-up) while being on anticoagulation, and patients with provoked thromboembolism.<xref ref-type="bibr" rid="article-23168.r63">[63]</xref><xref ref-type="bibr" rid="article-23168.r64">[64]</xref>&#x000a0;In cases of unprovoked thromboembolism, guidelines differ, and some suggest starting anticoagulation balancing risks and benefit without specific thrombophilia testing. Testing might be useful to exclude thrombophilia and stop anticoagulation. Testing to guide primary prevention in&#x000a0;relatives of asymptomatic VTE patients is not useful. Nevertheless, anticoagulation as primary prevention during exposure to provoking factors merits consideration.&#x000a0;Testing should be a two-staged approach or 3 months after finishing anticoagulation.<xref ref-type="bibr" rid="article-23168.r65">[65]</xref><xref ref-type="bibr" rid="article-23168.r66">[66]</xref>&#x000a0;Testing guidelines differ between medical societies.<xref ref-type="bibr" rid="article-23168.r67">[67]</xref><xref ref-type="bibr" rid="article-23168.r68">[68]</xref> Some&#x000a0;authors propose thrombophilia testing in patients with unprovoked or recurrent VTE, VTE in young patients (less than 40 years old), in patients with strong family history, thrombosis in unusual sites (cerebral, mesenteric, hepatic, renal), neonatal purpura fulminans, warfarin-induced skin necrosis, and fetal loss.<xref ref-type="bibr" rid="article-23168.r19">[19]</xref><xref ref-type="bibr" rid="article-23168.r11">[11]</xref><xref ref-type="bibr" rid="article-23168.r20">[20]</xref></p>
        <p>In patients with a history that brings up suspicion for APS (female, young age, recurrent VTE or fetal loss) unexplained PTT may prompt investigation for APS which are&#x000a0;Enzyme-linked immunosorbent assay (ELISA) testing for antiphospholipid antibodies,&#x000a0;the diluted Russell venom viper test (dRVVT) and PTT-LA.<xref ref-type="bibr" rid="article-23168.r12">[12]</xref>&#x000a0;The Sapporo criteria combine clinical and laboratory criteria to diagnose APS.</p>
        <p>As DVT and PE occur in up to 20% of patients with undetected cancer and unexplained VTE in older patients should prompt work-up for malignancy. Screening for cancer includes routine&#x000a0;(history and physical examination, ESR, CBC, liver and kidney function tests, urinalysis, and CXR) or extended investigations (tumor markers, CT of the chest, abdomen, and pelvis, mammography in women more than 40 years old, and prostate ultrasound in men older than 50 years, lower endoscopy, Papanicolaou smear, and fecal occult blood test).<xref ref-type="bibr" rid="article-23168.r8">[8]</xref><xref ref-type="bibr" rid="article-23168.r23">[23]</xref></p>
        <p>Up to 4% of strokes are due to coagulation disorders. The incidence of stroke in young adults is increasing gradually. In patients with&#x000a0;hypercoagulability syndromes, there is an increased risk of venous thrombosis than ischemic stroke. In some instances, venous thrombosis can also give rise to arterial strokes by paradoxical embolism, commonly through patent foramen ovale. So, young adults with stroke and a right to left shunt should be checked for venous thrombosis like deep vein thrombosis by ultrasound of lower extremities. The Homocystinuria and antiphospholipid antibody syndrome associated with arterial strokes. Stroke is the most common arterial event secondary to antiphospholipid antibody syndrome. Any stroke patient younger than 45 should be screened for&#x000a0;antiphospholipid antibody syndrome.</p>
      </sec>
      <sec id="article-23168.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The substitution of coagulation factors can achieve causal treatment.&#x000a0;ATIII can be substituted in cases of inherited (prophylaxis and treatment of ongoing thrombosis) or acquired deficiency (increased consumption in DIC and sepsis). Fresh frozen plasma (FFP) contains the natural balance of procoagulant and anticoagulant factors.</p>
        <p>Antithrombotic treatment decision should be based on a risk-benefit analysis.<xref ref-type="bibr" rid="article-23168.r69">[69]</xref> Tools to evaluate the individual risk of thrombosis include different scores such as&#x000a0;HERDOO, VIENNA, and DASH and the different thrombotic potential of thrombophilias (strong vs. weak thrombophilias) needs consideration.<xref ref-type="bibr" rid="article-23168.r70">[70]</xref><xref ref-type="bibr" rid="article-23168.r65">[65]</xref>&#x000a0;On the other side,&#x000a0;bleeding risk is assessable through the HAS-BLED, RIETE, OBRI, KUIJER, ACCP, HEMORR2HAGES, and ORBIT scores. The HAS-BLED score performed best to predict bleeding risk in patients with atrial fibrillation and is recommended in guidelines.<xref ref-type="bibr" rid="article-23168.r71">[71]</xref> Treatment duration following VTE divides into three phases: acute (a few days following the event), intermediate (short-term anticoagulation for three months) and chronic (long-term anticoagulation for more than 3 months).<xref ref-type="bibr" rid="article-23168.r72">[72]</xref> Factors such as male gender, age, proximal compared to distal deep vein thrombosis which&#x000a0;has a higher thrombotic burden, increased d-dimer, and unprovoked VTE implicate a higher recurrence rate and&#x000a0;can trigger extended coagulation.<xref ref-type="bibr" rid="article-23168.r73">[73]</xref>&#x000a0;Risk stratification&#x000a0;tools for the estimation of VTE recurrence in cancer include the COMPASS-CAT, Ottawa (Louzada) and Khorana scores.<xref ref-type="bibr" rid="article-23168.r74">[74]</xref><xref ref-type="bibr" rid="article-23168.r75">[75]</xref><xref ref-type="bibr" rid="article-23168.r76">[76]</xref><xref ref-type="bibr" rid="article-23168.r77">[77]</xref></p>
        <p>Different anticoagulants and antiplatelets are available to prevent recurrent VTE.<xref ref-type="bibr" rid="article-23168.r78">[78]</xref> They&#x000a0;include&#x000a0;vitamin K antagonist (VKA),&#x000a0;aspirin (as assessed in the WARFASA and ASPIRE trials),&#x000a0;rivaroxaban (EINSTEIN trial),&#x000a0;dabigatran (RE-MEDY and RE-SONATE trials), and&#x000a0;apixaban (AMPLIFY trial). Additional considerations are prudent regarding special populations. The CLOT trial assessed low molecular weight heparin against warfarin in cancer patients.&#x000a0;Heparin did not show teratogenicity and is FDA-approved&#x000a0;during pregnancy and the postpartum period.<xref ref-type="bibr" rid="article-23168.r20">[20]</xref><xref ref-type="bibr" rid="article-23168.r79">[79]</xref>&#x000a0;Prevention of thrombotic events includes compression stockings and mobility. Rosuvastatin&#x000a0;prevents the occurrence&#x000a0;of VTE.<xref ref-type="bibr" rid="article-23168.r80">[80]</xref></p>
      </sec>
      <sec id="article-23168.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>For&#x000a0;investigation of patients suffering from thrombotic events, it is essential to differentiate provoked and unprovoked thrombosis through history and physical. Thrombotic events are observable under diverse conditions. Therefore a broad differential diagnosis is essential including the more frequent (immobilization, travel) and less frequent entities such as cardiac disease (atrial fibrillation, cardiomyopathy, mitral valve prolapse, prosthetic valves), non-bacterial thrombotic endocarditis (NBTE) and hematologic causes such as disseminated intravascular coagulopathy (DIC) and heparin-induced thrombocytopenia (HIT).<xref ref-type="bibr" rid="article-23168.r81">[81]</xref><xref ref-type="bibr" rid="article-23168.r82">[82]</xref>&#x000a0;Clinical decision aids such as the HIT score can help to evaluate pretest probability and guide diagnostic workup.&#x000a0;</p>
        <p>Thrombophilia should be a differential diagnosis for vaso-occlusive events.&#x000a0; Arterial thrombosis such as osteonecrosis,<xref ref-type="bibr" rid="article-23168.r83">[83]</xref> ischemic stroke and myocardial infarction can be related to thrombophilia.<xref ref-type="bibr" rid="article-23168.r84">[84]</xref><xref ref-type="bibr" rid="article-23168.r85">[85]</xref><xref ref-type="bibr" rid="article-23168.r86">[86]</xref><xref ref-type="bibr" rid="article-23168.r87">[87]</xref>&#x000a0;Celik et al. investigated a population of young patients suffering from myocardial infarction. They concluded that the established cardiovascular risk factors but not thrombophilias contributed to myocardial infarction in young&#x000a0;patients.<xref ref-type="bibr" rid="article-23168.r88">[88]</xref>&#x000a0;Other studies&#x000a0;suggest to include thrombophilia in the differential diagnosis of myocardial infarction with non-occlusive coronary arteries (MINOCA).<xref ref-type="bibr" rid="article-23168.r89">[89]</xref><xref ref-type="bibr" rid="article-23168.r90">[90]</xref>&#x000a0;Thrombophilias might also be associated with stroke in young people by venous thromboembolism through a&#x000a0;patent foramen ovale.<xref ref-type="bibr" rid="article-23168.r91">[91]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-23168.s10" sec-type="Complications">
        <title>Complications</title>
        <p>Deep venous thrombosis has two major complications: pulmonary embolism, which is acute and life-threatening, and postthrombotic syndrome (PTS) with chronic venous ulceration (CVU).<xref ref-type="bibr" rid="article-23168.r92">[92]</xref> In one study more than 40% of patients with CVU had at least one thrombophilia, but the association between thrombophilia and micro- and macrovascular thrombosis leading to PTS and CVU remains unclear.<xref ref-type="bibr" rid="article-23168.r93">[93]</xref>&#x000a0;The two main complications are recurrent thrombosis or bleeding as a side effect of treatment. To avoid these individual risk assessment and therapy is necessary.&#x000a0;Micro- and macro thrombotic events in pregnancy can not only cause maternal death but can also cause fetal growth restriction, pregnancy loss, preeclampsia, and placental abruption.<xref ref-type="bibr" rid="article-23168.r79">[79]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-23168.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>When considering hemophilia testing (recurrent thromboembolic events, strong family history, etc.) referral to a hematologist should be considered.&#x000a0;</p>
      </sec>
      <sec id="article-23168.s12" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Thomas proposed the mnemonic <bold>CALMSHAPES</bold> to remember the causes of the hypercoagulable state.<xref ref-type="bibr" rid="article-23168.r8">[8]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Protein <bold>C</bold> deficiency</p>
          </list-item>
          <list-item>
            <p><bold>A</bold>ntiphospholipid syndrome</p>
          </list-item>
          <list-item>
            <p>Factor V<bold> L</bold>eiden mutation</p>
          </list-item>
          <list-item>
            <p><bold>M</bold>alignancy</p>
          </list-item>
          <list-item>
            <p>Protein <bold>S</bold> deficiency</p>
          </list-item>
          <list-item>
            <p><bold>H</bold>yperhomocysteinemia</p>
          </list-item>
          <list-item>
            <p><bold>A</bold>ntithrombin III deficiency</p>
          </list-item>
          <list-item>
            <p><bold>P</bold>rothrombin G2021A mutation</p>
          </list-item>
          <list-item>
            <p>Factor <bold>E</bold>ight excess</p>
          </list-item>
          <list-item>
            <p><bold>S</bold>ticky Platelet syndrome</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23168.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>It is essential to exercise prudence on when to test for thrombophilia. Considering the&#x000a0;negative&#x000a0;implications of a positive test for the individual (anxiety, bleeding risk) and costs should be balanced with the benefit of avoiding adverse effects from thrombotic events or miscarriage through anticoagulation.</p>
        <p>Prognostication implicates the question for the risks of recurrent thrombosis or bleeding as a side effect of anticoagulation. Patients with one VTE event have a 30% risk of recurrence in 10 years. Different&#x000a0;scoring systems are available to predict the risk of recurrence. Thrombosis carries a high in-hospital mortality and is the second most common cause of death in cancer patients.<xref ref-type="bibr" rid="article-23168.r23">[23]</xref></p>
        <p>an interprofessional&#x000a0;approach involving nurses and physicians in the evaluation and treatment of these patients results in the best outcomes. [Level V]</p>
      </sec>
      <sec id="article-23168.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23168&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23168">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/blood-disorders/hypercoagulability/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23168">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23168/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23168">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23168.s15">
        <title>References</title>
        <ref id="article-23168.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prandoni</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Venous and arterial thrombosis: Two aspects of the same disease?</article-title>
            <source>Clin Epidemiol</source>
            <year>2009</year>
            <month>Aug</month>
            <day>09</day>
            <volume>1</volume>
            <fpage>1</fpage>
            <page-range>1-6</page-range>
            <pub-id pub-id-type="pmid">20865079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Previtali</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bucciarelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Passamonti</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Martinelli</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for venous and arterial thrombosis.</article-title>
            <source>Blood Transfus</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>120</fpage>
            <page-range>120-38</page-range>
            <pub-id pub-id-type="pmid">21084000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>EGEBERG</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA.</article-title>
            <source>Thromb Diath Haemorrh</source>
            <year>1965</year>
            <month>Jun</month>
            <day>15</day>
            <volume>13</volume>
            <fpage>516</fpage>
            <page-range>516-30</page-range>
            <pub-id pub-id-type="pmid">14347873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Griffin</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Evatt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Kleiss</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Wideman</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Deficiency of protein C in congenital thrombotic disease.</article-title>
            <source>J Clin Invest</source>
            <year>1981</year>
            <month>Nov</month>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>1370</fpage>
            <page-range>1370-3</page-range>
            <pub-id pub-id-type="pmid">6895379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Comp</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Esmon</surname>
                <given-names>CT</given-names>
              </name>
            </person-group>
            <article-title>Recurrent venous thromboembolism in patients with a partial deficiency of protein S.</article-title>
            <source>N Engl J Med</source>
            <year>1984</year>
            <month>Dec</month>
            <day>13</day>
            <volume>311</volume>
            <issue>24</issue>
            <fpage>1525</fpage>
            <page-range>1525-8</page-range>
            <pub-id pub-id-type="pmid">6239102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dahlb&#x000e4;ck</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Svensson</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1993</year>
            <month>Feb</month>
            <day>01</day>
            <volume>90</volume>
            <issue>3</issue>
            <fpage>1004</fpage>
            <page-range>1004-8</page-range>
            <pub-id pub-id-type="pmid">8430067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dickerman</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Hereditary thrombophilia.</article-title>
            <source>Thromb J</source>
            <year>2006</year>
            <month>Sep</month>
            <day>12</day>
            <volume>4</volume>
            <fpage>15</fpage>
            <pub-id pub-id-type="pmid">16968541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Hypercoagulability syndromes.</article-title>
            <source>Arch Intern Med</source>
            <year>2001</year>
            <month>Nov</month>
            <day>12</day>
            <volume>161</volume>
            <issue>20</issue>
            <fpage>2433</fpage>
            <page-range>2433-9</page-range>
            <pub-id pub-id-type="pmid">11700155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Z&#x000f6;ller</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a de Frutos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hillarp</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dahlb&#x000e4;ck</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Thrombophilia as a multigenic disease.</article-title>
            <source>Haematologica</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>84</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-70</page-range>
            <pub-id pub-id-type="pmid">10091393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosendaal</surname>
                <given-names>FR</given-names>
              </name>
            </person-group>
            <article-title>Venous thrombosis: a multicausal disease.</article-title>
            <source>Lancet</source>
            <year>1999</year>
            <month>Apr</month>
            <day>03</day>
            <volume>353</volume>
            <issue>9159</issue>
            <fpage>1167</fpage>
            <page-range>1167-73</page-range>
            <pub-id pub-id-type="pmid">10209995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000e4;rz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Nauck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wieland</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The molecular mechanisms of inherited thrombophilia.</article-title>
            <source>Z Kardiol</source>
            <year>2000</year>
            <month>Jul</month>
            <volume>89</volume>
            <issue>7</issue>
            <fpage>575</fpage>
            <page-range>575-86</page-range>
            <pub-id pub-id-type="pmid">10957782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mazza</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Hypercoagulability and venous thromboembolism: a review.</article-title>
            <source>WMJ</source>
            <year>2004</year>
            <volume>103</volume>
            <issue>2</issue>
            <fpage>41</fpage>
            <page-range>41-9</page-range>
            <pub-id pub-id-type="pmid">15139558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosendaal</surname>
                <given-names>FR</given-names>
              </name>
            </person-group>
            <article-title>Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis.</article-title>
            <source>Thromb Haemost</source>
            <year>1997</year>
            <month>Jul</month>
            <volume>78</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-6</page-range>
            <pub-id pub-id-type="pmid">9198119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buchanan</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Ware Branch</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The inherited thrombophilias: genetics, epidemiology, and laboratory evaluation.</article-title>
            <source>Best Pract Res Clin Obstet Gynaecol</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>397</fpage>
            <page-range>397-411</page-range>
            <pub-id pub-id-type="pmid">12787534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Hanlin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Glurich</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mazza</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Yale</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Virchow's contribution to the understanding of thrombosis and cellular biology.</article-title>
            <source>Clin Med Res</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>3-4</issue>
            <fpage>168</fpage>
            <page-range>168-72</page-range>
            <pub-id pub-id-type="pmid">20739582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Byrnes</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Wolberg</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>New findings on venous thrombogenesis.</article-title>
            <source>Hamostaseologie</source>
            <year>2017</year>
            <month>Jan</month>
            <day>31</day>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-35</page-range>
            <pub-id pub-id-type="pmid">27878206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Esmon</surname>
                <given-names>CT</given-names>
              </name>
            </person-group>
            <article-title>Basic mechanisms and pathogenesis of venous thrombosis.</article-title>
            <source>Blood Rev</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>225</fpage>
            <page-range>225-9</page-range>
            <pub-id pub-id-type="pmid">19683659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolberg</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Aleman</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Leiderman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Machlus</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited.</article-title>
            <source>Anesth Analg</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>114</volume>
            <issue>2</issue>
            <fpage>275</fpage>
            <page-range>275-85</page-range>
            <pub-id pub-id-type="pmid">22104070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakashima</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants.</article-title>
            <source>Blood Res</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>49</volume>
            <issue>2</issue>
            <fpage>85</fpage>
            <page-range>85-94</page-range>
            <pub-id pub-id-type="pmid">25025009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Mureebe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Silver</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Hypercoagulable states: a review.</article-title>
            <source>Vasc Endovascular Surg</source>
            <year>2005</year>
            <season>Mar-Apr</season>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <page-range>123-33</page-range>
            <pub-id pub-id-type="pmid">15806273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saadah</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Thakre</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Saadah</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Nazzal</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Homocystinemia and stroke in vegetarians.</article-title>
            <source>Neurosciences (Riyadh)</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>107</fpage>
            <page-range>107-11</page-range>
            <pub-id pub-id-type="pmid">22266560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aras</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sowers</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The proinflammatory and hypercoagulable state of diabetes mellitus.</article-title>
            <source>Rev Cardiovasc Med</source>
            <year>2005</year>
            <season>Spring</season>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>84</fpage>
            <page-range>84-97</page-range>
            <pub-id pub-id-type="pmid">15976731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caine</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Stonelake</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Kehoe</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>The hypercoagulable state of malignancy: pathogenesis and current debate.</article-title>
            <source>Neoplasia</source>
            <year>2002</year>
            <season>Nov-Dec</season>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>465</fpage>
            <page-range>465-73</page-range>
            <pub-id pub-id-type="pmid">12407439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khorana</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Malignancy, thrombosis and Trousseau: the case for an eponym.</article-title>
            <source>J Thromb Haemost</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>1</volume>
            <issue>12</issue>
            <fpage>2463</fpage>
            <page-range>2463-5</page-range>
            <pub-id pub-id-type="pmid">14675077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rickles</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Activation of blood coagulation in cancer: Trousseau's syndrome revisited.</article-title>
            <source>Blood</source>
            <year>1983</year>
            <month>Jul</month>
            <volume>62</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-31</page-range>
            <pub-id pub-id-type="pmid">6407544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lima</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Monteiro</surname>
                <given-names>RQ</given-names>
              </name>
            </person-group>
            <article-title>Activation of blood coagulation in cancer: implications for tumour progression.</article-title>
            <source>Biosci Rep</source>
            <year>2013</year>
            <month>Sep</month>
            <day>04</day>
            <volume>33</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">23889169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steffel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>L&#x000fc;scher</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Tanner</surname>
                <given-names>FC</given-names>
              </name>
            </person-group>
            <article-title>Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications.</article-title>
            <source>Circulation</source>
            <year>2006</year>
            <month>Feb</month>
            <day>07</day>
            <volume>113</volume>
            <issue>5</issue>
            <fpage>722</fpage>
            <page-range>722-31</page-range>
            <pub-id pub-id-type="pmid">16461845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Posthuma</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>van der Meijden</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Ten Cate</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Spronk</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Short- and Long-term exercise induced alterations in haemostasis: a review of the literature.</article-title>
            <source>Blood Rev</source>
            <year>2015</year>
            <month>May</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>171</fpage>
            <page-range>171-8</page-range>
            <pub-id pub-id-type="pmid">25467962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yorifuji</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ikematsu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nagasawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fujimaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fukutake</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Katsumura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iwane</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Influences of strenuous exercise (triathlon) on blood coagulation and fibrinolytic system.</article-title>
            <source>Thromb Res</source>
            <year>1990</year>
            <month>Feb</month>
            <day>01</day>
            <volume>57</volume>
            <issue>3</issue>
            <fpage>465</fpage>
            <page-range>465-71</page-range>
            <pub-id pub-id-type="pmid">2315896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Effects of strenuous exercise on haemostasis.</article-title>
            <source>Br J Sports Med</source>
            <year>2003</year>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>433</fpage>
            <page-range>433-5</page-range>
            <pub-id pub-id-type="pmid">14514536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>R&#x000f6;cker</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Drygas</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Heyduck</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Blood platelet activation and increase in thrombin activity following a marathon race.</article-title>
            <source>Eur J Appl Physiol Occup Physiol</source>
            <year>1986</year>
            <volume>55</volume>
            <issue>4</issue>
            <fpage>374</fpage>
            <page-range>374-80</page-range>
            <pub-id pub-id-type="pmid">3758037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rinde</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Lind</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sm&#x000e5;brekke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nj&#x000f8;lstad</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mathiesen</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Wilsgaard</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>L&#x000f8;chen</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Hald</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Vik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Braekkan</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Impact of incident myocardial infarction on the risk of venous thromboembolism: the Troms&#x000f8; Study.</article-title>
            <source>J Thromb Haemost</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>1183</fpage>
            <page-range>1183-91</page-range>
            <pub-id pub-id-type="pmid">27061154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borch</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Hansen-Krone</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Braekkan</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Mathiesen</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Njolstad</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wilsgaard</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Physical activity and risk of venous thromboembolism. The Tromso study.</article-title>
            <source>Haematologica</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>95</volume>
            <issue>12</issue>
            <fpage>2088</fpage>
            <page-range>2088-94</page-range>
            <pub-id pub-id-type="pmid">20801904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andreotti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Hackett</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>De Bart</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Aber</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Maseri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kluft</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke.</article-title>
            <source>Am J Cardiol</source>
            <year>1988</year>
            <month>Sep</month>
            <day>15</day>
            <volume>62</volume>
            <issue>9</issue>
            <fpage>635</fpage>
            <page-range>635-7</page-range>
            <pub-id pub-id-type="pmid">3137799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elliott</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Circadian variation in the timing of stroke onset: a meta-analysis.</article-title>
            <source>Stroke</source>
            <year>1998</year>
            <month>May</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>992</fpage>
            <page-range>992-6</page-range>
            <pub-id pub-id-type="pmid">9596248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jafri</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>VanRollins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ozawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mammen</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Circadian variation in platelet function in healthy volunteers.</article-title>
            <source>Am J Cardiol</source>
            <year>1992</year>
            <month>Apr</month>
            <day>01</day>
            <volume>69</volume>
            <issue>9</issue>
            <fpage>951</fpage>
            <page-range>951-4</page-range>
            <pub-id pub-id-type="pmid">1532287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Inamizu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sekikawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kakehashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Onari</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Determinants of the daily rhythm of blood fluidity.</article-title>
            <source>J Circadian Rhythms</source>
            <year>2009</year>
            <month>Jun</month>
            <day>26</day>
            <volume>7</volume>
            <fpage>7</fpage>
            <pub-id pub-id-type="pmid">19558641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinotti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bertolucci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Portaluppi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Colognesi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Frigato</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fo&#x000e0;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bernardi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Daily and circadian rhythms of tissue factor pathway inhibitor and factor VII activity.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>646</fpage>
            <page-range>646-9</page-range>
            <pub-id pub-id-type="pmid">15604416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Effects of diet composition on coagulation pathways.</article-title>
            <source>Am J Clin Nutr</source>
            <year>1998</year>
            <month>Mar</month>
            <volume>67</volume>
            <issue>3 Suppl</issue>
            <fpage>542S</fpage>
            <page-range>542S-545S</page-range>
            <pub-id pub-id-type="pmid">9497167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freedman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Glueck</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Prince</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Riaz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Testosterone, thrombophilia, thrombosis.</article-title>
            <source>Transl Res</source>
            <year>2015</year>
            <month>May</month>
            <volume>165</volume>
            <issue>5</issue>
            <fpage>537</fpage>
            <page-range>537-48</page-range>
            <pub-id pub-id-type="pmid">25639953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glueck</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Richardson-Royer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bowe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Padda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Testosterone therapy, thrombophilia-hypofibrinolysis, and hospitalization for deep venous thrombosis-pulmonary embolus: an exploratory, hypothesis-generating study.</article-title>
            <source>Clin Appl Thromb Hemost</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>244</fpage>
            <page-range>244-9</page-range>
            <pub-id pub-id-type="pmid">23925401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pomp</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Lenselink</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rosendaal</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Doggen</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study.</article-title>
            <source>J Thromb Haemost</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>632</fpage>
            <page-range>632-7</page-range>
            <pub-id pub-id-type="pmid">18248600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Jong</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Quenby</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bloemenkamp</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Braams-Lisman</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>de Bruin</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Coomarasamy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>DeSancho</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>van der Heijden</surname>
                <given-names>OW</given-names>
              </name>
              <name>
                <surname>Hoek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hutten</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Jochmans</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Koks</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Kuchenbecker</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Mol</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Torrance</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Scheepers</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Stephenson</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Verhoeve</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Visser</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Goddijn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Middeldorp</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia--study protocol for a randomized controlled trial.</article-title>
            <source>Trials</source>
            <year>2015</year>
            <month>May</month>
            <day>07</day>
            <volume>16</volume>
            <fpage>208</fpage>
            <pub-id pub-id-type="pmid">25947329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Middeldorp</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Thrombophilia and pregnancy complications: cause or association?</article-title>
            <source>J Thromb Haemost</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>5 Suppl 1</volume>
            <fpage>276</fpage>
            <page-range>276-82</page-range>
            <pub-id pub-id-type="pmid">17635737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delvaeye</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Conway</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Coagulation and innate immune responses: can we view them separately?</article-title>
            <source>Blood</source>
            <year>2009</year>
            <month>Sep</month>
            <day>17</day>
            <volume>114</volume>
            <issue>12</issue>
            <fpage>2367</fpage>
            <page-range>2367-74</page-range>
            <pub-id pub-id-type="pmid">19584396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kane</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Interactions of the classical and alternate complement pathway with endotoxin lipopolysaccharide. Effect on platelets and blood coagulation.</article-title>
            <source>J Clin Invest</source>
            <year>1973</year>
            <month>Feb</month>
            <volume>52</volume>
            <issue>2</issue>
            <fpage>370</fpage>
            <page-range>370-6</page-range>
            <pub-id pub-id-type="pmid">4683877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Emmi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Silvestri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Squatrito</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Amedei</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Niccolai</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>D'Elios</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Della Bella</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grassi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Becatti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fiorillo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Emmi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vaglio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Prisco</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Thrombosis in vasculitis: from pathogenesis to treatment.</article-title>
            <source>Thromb J</source>
            <year>2015</year>
            <volume>13</volume>
            <fpage>15</fpage>
            <pub-id pub-id-type="pmid">25883536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomasson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Monach</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Thromboembolic disease in vasculitis.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-6</page-range>
            <pub-id pub-id-type="pmid">19077717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Z&#x000f6;ller</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Sundquist</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sundquist</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune diseases and venous thromboembolism: a review of the literature.</article-title>
            <source>Am J Cardiovasc Dis</source>
            <year>2012</year>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>171</fpage>
            <page-range>171-83</page-range>
            <pub-id pub-id-type="pmid">22937487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kravitz</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Shoenfeld</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Thrombocytopenic conditions-autoimmunity and hypercoagulability: commonalities and differences in ITP, TTP, HIT, and APS.</article-title>
            <source>Am J Hematol</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>80</volume>
            <issue>3</issue>
            <fpage>232</fpage>
            <page-range>232-42</page-range>
            <pub-id pub-id-type="pmid">16247748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Khasnis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Venous thromboembolism in systemic autoimmune diseases: A narrative review with emphasis on primary systemic vasculitides.</article-title>
            <source>Vasc Med</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>369</fpage>
            <page-range>369-76</page-range>
            <pub-id pub-id-type="pmid">25750012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nieto</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Sorlie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Comstock</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Adam</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Melnick</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Szklo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cytomegalovirus infection, lipoprotein(a), and hypercoagulability: an atherogenic link?</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>1997</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>1780</fpage>
            <page-range>1780-5</page-range>
            <pub-id pub-id-type="pmid">9327777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schreiber</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Differding</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thorborg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mayberry</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Mullins</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Hypercoagulability is most prevalent early after injury and in female patients.</article-title>
            <source>J Trauma</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>475</fpage>
            <page-range>475-80; discussion 480-1</page-range>
            <pub-id pub-id-type="pmid">15761339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kristinsson</surname>
                <given-names>SY</given-names>
              </name>
            </person-group>
            <article-title>Thrombosis in multiple myeloma.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2010</year>
            <volume>2010</volume>
            <fpage>437</fpage>
            <page-range>437-44</page-range>
            <pub-id pub-id-type="pmid">21239832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lip</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Does heart failure confer a hypercoagulable state? Virchow's triad revisited.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>1424</fpage>
            <page-range>1424-6</page-range>
            <pub-id pub-id-type="pmid">10193748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Breitenstein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Glanzmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Maisano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>St&#x000e4;mpfli</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Holy</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Finlay</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Schilling</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>L&#x000fc;scher</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Steffel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Camici</surname>
                <given-names>GG</given-names>
              </name>
            </person-group>
            <article-title>Increased prothrombotic profile in the left atrial appendage of atrial fibrillation patients.</article-title>
            <source>Int J Cardiol</source>
            <year>2015</year>
            <month>Apr</month>
            <day>15</day>
            <volume>185</volume>
            <fpage>250</fpage>
            <page-range>250-5</page-range>
            <pub-id pub-id-type="pmid">25814212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smalberg</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kruip</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Rijken</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Leebeek</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>de Maat</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: similarities and differences.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>485</fpage>
            <page-range>485-93</page-range>
            <pub-id pub-id-type="pmid">21325670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohanty</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shetty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pawar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India.</article-title>
            <source>Hepatology</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>34</volume>
            <issue>4 Pt 1</issue>
            <fpage>666</fpage>
            <page-range>666-70</page-range>
            <pub-id pub-id-type="pmid">11584361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bombeli</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Basic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fehr</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems.</article-title>
            <source>Am J Hematol</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>70</volume>
            <issue>2</issue>
            <fpage>126</fpage>
            <page-range>126-32</page-range>
            <pub-id pub-id-type="pmid">12111785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lussana</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dentali</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ageno</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kamphuisen</surname>
                <given-names>PW</given-names>
              </name>
            </person-group>
            <article-title>Venous thrombosis at unusual sites and the role of thrombophilia.</article-title>
            <source>Semin Thromb Hemost</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>582</fpage>
            <page-range>582-7</page-range>
            <pub-id pub-id-type="pmid">17768690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riva</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ageno</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Approach to thrombosis at unusual sites: Splanchnic and cerebral vein thrombosis.</article-title>
            <source>Vasc Med</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>529</fpage>
            <page-range>529-540</page-range>
            <pub-id pub-id-type="pmid">29202678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Micco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>D'Uva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Strina</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mollo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amato</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Niglio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Placido</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The role of d-dimer as first marker of thrombophilia in women affected by sterility: implications in pathophysiology and diagnosis of thrombophilia induced sterility.</article-title>
            <source>J Transl Med</source>
            <year>2004</year>
            <month>Nov</month>
            <day>09</day>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <pub-id pub-id-type="pmid">15535889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moll</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Thrombophilia: clinical-practical aspects.</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>367</fpage>
            <page-range>367-78</page-range>
            <pub-id pub-id-type="pmid">25724822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Middeldorp</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Is thrombophilia testing useful?</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2011</year>
            <volume>2011</volume>
            <fpage>150</fpage>
            <page-range>150-5</page-range>
            <pub-id pub-id-type="pmid">22160027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stevens</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Woller</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Kasthuri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Streiff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Douketis</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Guidance for the evaluation and treatment of hereditary and acquired thrombophilia.</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>154</fpage>
            <page-range>154-64</page-range>
            <pub-id pub-id-type="pmid">26780744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinelli</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Pros and cons of thrombophilia testing: pros.</article-title>
            <source>J Thromb Haemost</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>410</fpage>
            <page-range>410-1</page-range>
            <pub-id pub-id-type="pmid">12871438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Connors</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Thrombophilia Testing and Venous Thrombosis.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Sep</month>
            <day>21</day>
            <volume>377</volume>
            <issue>12</issue>
            <fpage>1177</fpage>
            <page-range>1177-1187</page-range>
            <pub-id pub-id-type="pmid">28930509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Machin</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Pros and cons of thrombophilia testing: cons.</article-title>
            <source>J Thromb Haemost</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>412</fpage>
            <page-range>412-3</page-range>
            <pub-id pub-id-type="pmid">12871439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldhaber</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Piazza</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Optimal duration of anticoagulation after venous thromboembolism.</article-title>
            <source>Circulation</source>
            <year>2011</year>
            <month>Feb</month>
            <day>15</day>
            <volume>123</volume>
            <issue>6</issue>
            <fpage>664</fpage>
            <page-range>664-7</page-range>
            <pub-id pub-id-type="pmid">21321182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Makris</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Thrombophilia: grading the risk.</article-title>
            <source>Blood</source>
            <year>2009</year>
            <month>May</month>
            <day>21</day>
            <volume>113</volume>
            <issue>21</issue>
            <fpage>5038</fpage>
            <page-range>5038-9</page-range>
            <pub-id pub-id-type="pmid">19470434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Apostolakis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Buller</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GY</given-names>
              </name>
            </person-group>
            <article-title>Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2012</year>
            <month>Aug</month>
            <day>28</day>
            <volume>60</volume>
            <issue>9</issue>
            <fpage>861</fpage>
            <page-range>861-7</page-range>
            <pub-id pub-id-type="pmid">22858389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fahrni</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Husmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gretener</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Keo</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Assessing the risk of recurrent venous thromboembolism--a practical approach.</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2015</year>
            <volume>11</volume>
            <fpage>451</fpage>
            <page-range>451-9</page-range>
            <pub-id pub-id-type="pmid">26316770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Douketis</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Ginsberg</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis?</article-title>
            <source>Am J Med</source>
            <year>2001</year>
            <month>May</month>
            <volume>110</volume>
            <issue>7</issue>
            <fpage>515</fpage>
            <page-range>515-9</page-range>
            <pub-id pub-id-type="pmid">11343664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menapace</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>McCrae</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Khorana</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Predictors of recurrent venous thromboembolism and bleeding on anticoagulation.</article-title>
            <source>Thromb Res</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>140 Suppl 1</volume>
            <fpage>S93</fpage>
            <page-range>S93-8</page-range>
            <pub-id pub-id-type="pmid">27067987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agnelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Becattini</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>471</fpage>
            <page-range>471-7</page-range>
            <pub-id pub-id-type="pmid">24319221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thaler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ay</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pabinger</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials.</article-title>
            <source>Thromb Haemost</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>108</volume>
            <issue>6</issue>
            <fpage>1042</fpage>
            <page-range>1042-8</page-range>
            <pub-id pub-id-type="pmid">22836491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerotziafas</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Taher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abdel-Razeq</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>AboElnazar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Spyropoulos</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>El Shemmari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Elalamy</surname>
                <given-names>I</given-names>
              </name>
              <collab>COMPASS&#x02013;CAT Working Group</collab>
            </person-group>
            <article-title>A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study.</article-title>
            <source>Oncologist</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>10</issue>
            <fpage>1222</fpage>
            <page-range>1222-1231</page-range>
            <pub-id pub-id-type="pmid">28550032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnes</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Kanthi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Froehlich</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation.</article-title>
            <source>Vasc Med</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>143</fpage>
            <page-range>143-52</page-range>
            <pub-id pub-id-type="pmid">25832602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ormesher</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Simcox</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tower</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>IA</given-names>
              </name>
            </person-group>
            <article-title>Management of inherited thrombophilia in pregnancy.</article-title>
            <source>Womens Health (Lond)</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>433</fpage>
            <page-range>433-41</page-range>
            <pub-id pub-id-type="pmid">27638899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glynn</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Danielson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Genest</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gotto</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kastelein</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Koenig</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Libby</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lorenzatti</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>MacFadyen</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Shepherd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Willerson</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Ridker</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>A randomized trial of rosuvastatin in the prevention of venous thromboembolism.</article-title>
            <source>N Engl J Med</source>
            <year>2009</year>
            <month>Apr</month>
            <day>30</day>
            <volume>360</volume>
            <issue>18</issue>
            <fpage>1851</fpage>
            <page-range>1851-61</page-range>
            <pub-id pub-id-type="pmid">19329822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Andreotti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Hypercoagulable states in cardiovascular disease.</article-title>
            <source>Circulation</source>
            <year>2008</year>
            <month>Nov</month>
            <day>25</day>
            <volume>118</volume>
            <issue>22</issue>
            <fpage>2286</fpage>
            <page-range>2286-97</page-range>
            <pub-id pub-id-type="pmid">19029477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kitchens</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Concept of hypercoagulability: a review of its development, clinical application, and recent progress.</article-title>
            <source>Semin Thromb Hemost</source>
            <year>1985</year>
            <month>Jul</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>293</fpage>
            <page-range>293-315</page-range>
            <pub-id pub-id-type="pmid">3901260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glueck</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Freiberg</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Heritable thrombophilia-hypofibrinolysis and osteonecrosis of the femoral head.</article-title>
            <source>Clin Orthop Relat Res</source>
            <year>2008</year>
            <month>May</month>
            <volume>466</volume>
            <issue>5</issue>
            <fpage>1034</fpage>
            <page-range>1034-40</page-range>
            <pub-id pub-id-type="pmid">18350351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegerink</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Maino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Algra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosendaal</surname>
                <given-names>FR</given-names>
              </name>
            </person-group>
            <article-title>Hypercoagulability and the risk of myocardial infarction and ischemic stroke in young women.</article-title>
            <source>J Thromb Haemost</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>1568</fpage>
            <page-range>1568-75</page-range>
            <pub-id pub-id-type="pmid">26178535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Loh</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>VK</given-names>
              </name>
            </person-group>
            <article-title>Role of investigating thrombophilic disorders in young stroke.</article-title>
            <source>Stroke Res Treat</source>
            <year>2011</year>
            <month>Feb</month>
            <day>08</day>
            <volume>2011</volume>
            <fpage>670138</fpage>
            <pub-id pub-id-type="pmid">21331344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hankey</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Eikelboom</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>van Bockxmeer</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Lofthouse</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Staples</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>RI</given-names>
              </name>
            </person-group>
            <article-title>Inherited thrombophilia in ischemic stroke and its pathogenic subtypes.</article-title>
            <source>Stroke</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>32</volume>
            <issue>8</issue>
            <fpage>1793</fpage>
            <page-range>1793-9</page-range>
            <pub-id pub-id-type="pmid">11486107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maor</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fefer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Varon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Levi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hod</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Matetzky</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Thrombophilic state in young patients with acute myocardial infarction.</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2015</year>
            <month>May</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>474</fpage>
            <page-range>474-80</page-range>
            <pub-id pub-id-type="pmid">25589366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Celik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Altintas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Celik</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Karabulut</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ayyildiz</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Thrombophilia in young patients with acute myocardial infarction.</article-title>
            <source>Saudi Med J</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-54</page-range>
            <pub-id pub-id-type="pmid">18176672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hubert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gu&#x000e9;ret</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leurent</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martins</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Auffret</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bedossa</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Myocardial infarction and thrombophilia: Do not miss the right diagnosis!</article-title>
            <source>Rev Port Cardiol (Engl Ed)</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>89.e1</fpage>
            <page-range>89.e1-89.e4</page-range>
            <pub-id pub-id-type="pmid">29254740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Segev</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Segev</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Reshef</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sparkes</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Tetro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pauzner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors.</article-title>
            <source>Int J Cardiol</source>
            <year>2005</year>
            <month>Feb</month>
            <day>28</day>
            <volume>98</volume>
            <issue>3</issue>
            <fpage>421</fpage>
            <page-range>421-4</page-range>
            <pub-id pub-id-type="pmid">15708174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Offelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zanchetta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pedon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Marzot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cucchini</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Pegoraro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Iliceto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pengo</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Thrombophilia in young patients with cryptogenic stroke and patent foramen ovale (PFO).</article-title>
            <source>Thromb Haemost</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>98</volume>
            <issue>4</issue>
            <fpage>906</fpage>
            <page-range>906-7</page-range>
            <pub-id pub-id-type="pmid">17938820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rabinovich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Association between Thrombophilia and the Post-Thrombotic Syndrome.</article-title>
            <source>Int J Vasc Med</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>643036</fpage>
            <pub-id pub-id-type="pmid">23762560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23168.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mackenzie</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Ludlam</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Ruckley</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Allan</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bradbury</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>The prevalence of thrombophilia in patients with chronic venous leg ulceration.</article-title>
            <source>J Vasc Surg</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>718</fpage>
            <page-range>718-22</page-range>
            <pub-id pub-id-type="pmid">11932669</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
